questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Sirtuines
Sirtuine-1
Sirtuine-1 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Complement C3-C5 Convertases
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sirtuine-1 : Questions médicales les plus fréquentes",
"headline": "Sirtuine-1 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sirtuine-1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-13",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sirtuine-1"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sirtuines",
"url": "https://questionsmedicales.fr/mesh/D037761",
"about": {
"@type": "MedicalCondition",
"name": "Sirtuines",
"code": {
"@type": "MedicalCode",
"code": "D037761",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.900"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sirtuine-1",
"alternateName": "Sirtuin 1",
"code": {
"@type": "MedicalCode",
"code": "D056564",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Giulia Bononi",
"url": "https://questionsmedicales.fr/author/Giulia%20Bononi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
},
{
"@type": "Person",
"name": "Valentina Citi",
"url": "https://questionsmedicales.fr/author/Valentina%20Citi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
},
{
"@type": "Person",
"name": "Alma Martelli",
"url": "https://questionsmedicales.fr/author/Alma%20Martelli",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
},
{
"@type": "Person",
"name": "Giulio Poli",
"url": "https://questionsmedicales.fr/author/Giulio%20Poli",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
},
{
"@type": "Person",
"name": "Tiziano Tuccinardi",
"url": "https://questionsmedicales.fr/author/Tiziano%20Tuccinardi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Defining Nephritic Factors as Diverse Drivers of Systemic Complement Dysregulation in C3 Glomerulopathy.",
"datePublished": "2023-11-30",
"url": "https://questionsmedicales.fr/article/38344720",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ekir.2023.11.025"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characterization of complement C3 as a marker of alpha-amanitin toxicity by comparative secretome profiling.",
"datePublished": "2022-12-22",
"url": "https://questionsmedicales.fr/article/37008699",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s43188-022-00163-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Interactions of Candida tropicalis pH-related antigen 1 with complement proteins C3, C3b, factor-H, C4BP and complement evasion.",
"datePublished": "2022-11-23",
"url": "https://questionsmedicales.fr/article/36495597",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.imbio.2022.152303"
}
},
{
"@type": "ScholarlyArticle",
"name": "COMPLEMENT-MEDIATED THROMBOTIC MICROANGIOPATHY AFTER KIDNEY TRANSPLANT: SHOULD TREATMENT WITH C5 INHIBITOR BE LIFELONG?",
"datePublished": "2024-04-14",
"url": "https://questionsmedicales.fr/article/38615653",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000538826"
}
},
{
"@type": "ScholarlyArticle",
"name": "Outcome of atypical hemolytic uremic syndrome: role of triggers and complement abnormalities in the response to C5 inhibition.",
"datePublished": "2024-01-27",
"url": "https://questionsmedicales.fr/article/38280096",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40620-023-01873-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sirtuines",
"item": "https://questionsmedicales.fr/mesh/D037761"
},
{
"@type": "ListItem",
"position": 6,
"name": "Sirtuine-1",
"item": "https://questionsmedicales.fr/mesh/D056564"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sirtuine-1 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sirtuine-1",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sirtuine-1",
"description": "Comment évaluer le niveau de Sirtuine-1 ?\nQuels tests sont utilisés pour la Sirtuine-1 ?\nY a-t-il des biomarqueurs associés à Sirtuine-1 ?\nLa génétique influence-t-elle Sirtuine-1 ?\nPeut-on mesurer Sirtuine-1 dans les tissus ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sirtuine-1",
"description": "Quels symptômes sont liés à une faible Sirtuine-1 ?\nLa Sirtuine-1 affecte-t-elle le vieillissement ?\nQuels effets sur la santé mentale ?\nY a-t-il des symptômes de maladies liées à Sirtuine-1 ?\nSirtuine-1 influence-t-elle l'énergie cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sirtuine-1",
"description": "Comment prévenir la baisse de Sirtuine-1 ?\nLe stress affecte-t-il Sirtuine-1 ?\nY a-t-il des habitudes à éviter ?\nLe sommeil influence-t-il Sirtuine-1 ?\nDes suppléments pour Sirtuine-1 ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sirtuine-1",
"description": "Quels traitements augmentent Sirtuine-1 ?\nY a-t-il des médicaments ciblant Sirtuine-1 ?\nComment la nutrition affecte-t-elle Sirtuine-1 ?\nL'exercice physique influence-t-il Sirtuine-1 ?\nDes thérapies géniques pour Sirtuine-1 ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sirtuine-1",
"description": "Quelles complications sont liées à une faible Sirtuine-1 ?\nSirtuine-1 et maladies cardiovasculaires ?\nY a-t-il un lien avec le diabète ?\nSirtuine-1 et cancer ?\nComplications neurologiques liées à Sirtuine-1 ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sirtuine-1",
"description": "Quels facteurs augmentent le risque de faible Sirtuine-1 ?\nL'alimentation influence-t-elle Sirtuine-1 ?\nLe mode de vie sédentaire affecte-t-il Sirtuine-1 ?\nLe tabagisme impacte-t-il Sirtuine-1 ?\nLe stress oxydatif influence-t-il Sirtuine-1 ?",
"url": "https://questionsmedicales.fr/mesh/D056564?mesh_terms=Complement+C3-C5+Convertases&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer le niveau de Sirtuine-1 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le niveau de Sirtuine-1 peut être mesuré par des tests sanguins ou des biopsies tissulaires."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour la Sirtuine-1 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques et des analyses protéomiques sont utilisés pour évaluer Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à Sirtuine-1 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biomarqueurs comme les niveaux de NAD+ peuvent être associés à Sirtuine-1."
}
},
{
"@type": "Question",
"name": "La génétique influence-t-elle Sirtuine-1 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent affecter l'expression de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer Sirtuine-1 dans les tissus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Sirtuine-1 peut être mesurée dans des échantillons de tissus par immunohistochimie."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une faible Sirtuine-1 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une faible Sirtuine-1 peut être associée à des troubles métaboliques et à l'inflammation."
}
},
{
"@type": "Question",
"name": "La Sirtuine-1 affecte-t-elle le vieillissement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Sirtuine-1 est impliquée dans la régulation du vieillissement cellulaire et de la longévité."
}
},
{
"@type": "Question",
"name": "Quels effets sur la santé mentale ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de Sirtuine-1 peuvent influencer l'humeur et la cognition."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes de maladies liées à Sirtuine-1 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète et les maladies neurodégénératives sont liées à Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Sirtuine-1 influence-t-elle l'énergie cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Sirtuine-1 joue un rôle clé dans la régulation de l'énergie cellulaire et du métabolisme."
}
},
{
"@type": "Question",
"name": "Comment prévenir la baisse de Sirtuine-1 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain avec une bonne nutrition et de l'exercice aide à prévenir la baisse."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il Sirtuine-1 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut réduire l'expression de Sirtuine-1 dans les cellules."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une alimentation riche en sucres peut aider à maintenir Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Le sommeil influence-t-il Sirtuine-1 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un sommeil de qualité est essentiel pour maintenir des niveaux optimaux de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Des suppléments pour Sirtuine-1 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments comme le resvératrol peuvent être bénéfiques pour soutenir Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Quels traitements augmentent Sirtuine-1 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme le resvératrol et l'exercice physique peuvent augmenter Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments ciblant Sirtuine-1 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments expérimentaux visent à moduler l'activité de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Comment la nutrition affecte-t-elle Sirtuine-1 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en polyphénols peut stimuler l'expression de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "L'exercice physique influence-t-il Sirtuine-1 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier est connu pour augmenter les niveaux de Sirtuine-1 dans le corps."
}
},
{
"@type": "Question",
"name": "Des thérapies géniques pour Sirtuine-1 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour moduler Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à une faible Sirtuine-1 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une faible Sirtuine-1 est liée à des maladies métaboliques et à des troubles neurodégénératifs."
}
},
{
"@type": "Question",
"name": "Sirtuine-1 et maladies cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux bas de Sirtuine-1 peuvent augmenter le risque de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une faible Sirtuine-1 est associée à une résistance à l'insuline et au diabète de type 2."
}
},
{
"@type": "Question",
"name": "Sirtuine-1 et cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que Sirtuine-1 pourrait jouer un rôle dans la progression de certains cancers."
}
},
{
"@type": "Question",
"name": "Complications neurologiques liées à Sirtuine-1 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une dysrégulation de Sirtuine-1 est liée à des maladies comme Alzheimer et Parkinson."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de faible Sirtuine-1 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le vieillissement et le stress chronique augmentent le risque de faible Sirtuine-1."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle Sirtuine-1 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation pauvre en nutriments peut réduire l'expression de Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Le mode de vie sédentaire affecte-t-il Sirtuine-1 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire est un facteur de risque pour une faible Sirtuine-1."
}
},
{
"@type": "Question",
"name": "Le tabagisme impacte-t-il Sirtuine-1 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est associé à une diminution des niveaux de Sirtuine-1 dans l'organisme."
}
},
{
"@type": "Question",
"name": "Le stress oxydatif influence-t-il Sirtuine-1 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress oxydatif peut réduire l'activité de Sirtuine-1 et affecter la santé cellulaire."
}
}
]
}
]
}
C3 glomerulopathy (C3G) is an ultrarare renal disease characterized by deposition of complement component C3 in the glomerular basement membrane (GBM). Rare and novel genetic variation in complement g...
Here, we present a retrospective analysis of the Molecular Otolaryngology and Renal Research Laboratories C3G cohort. This study integrated complement biomarker testing and...
The largest disease profiles of C3G included patients with autoantibodies to complement proteins (48%) and patients for whom no genetic and/or acquired drivers of disease could be identified (43%). Th...
This study implicates complement autoantibodies as robust drivers of systemic complement dysregulation in approximately 50% of C3G but also highlights the need for continued discovery-based research t...
In the human body, proteins secreted into peripheral blood vessels are known as the secretome, and they represent the physiological or pathological status of cells. The unique response of cells to tox...
The online version contains supplementary material available at 10.1007/s43188-022-00163-z....
Candida, as a part of the human microbiota, can cause opportunistic infections that are either localised or systemic candidiasis. Emerging resistance to the standard antifungal drugs is associated wit...
Complement-mediated thrombotic microangiopathy (CM-TMA) is a rare and life-threatening complication that can occur in kidney transplant recipients, with various potential triggers including immunosupp...
Atypical-hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy often due to uncontrolled complement activation, characterized by high risk of end-stage kidney disease (ESKD). Eculizuma...
To identify characteristics associated with treatment response, we analyzed 244 aHUS patients referred to our center. Patients were classified according to the presence/absence of complement abnormali...
Patients had a better outcome with eculizumab compared to conventional treatment, with a response rate of 81.9% vs 56.9%, p < 0.001 and a long-term cumulative incidence of ESKD of 5.8% vs 22.5% (hazar...
Our data show a better outcome in aHUS patients treated with C5-inhibition, particularly in the primary and combined forms, which have a high risk of relapse after discontinuation that is not observed...
Changes in N-glycosylation have been described in numerous diseases and are being considered as biomarkers of ongoing pathological condition. Previous studies demonstrated the interrelation of N-glyco...
Complement component C3 N-glycosylation profiles have been analyzed from 189 serum samples of T1D patients (median age 46) recruited at a Croatian hospital centre. Using our recently developed high-th...
Significant changes of C3 N-glycome in severe albuminuria accompanying type 1 diabetes were observed, as well as in T1D subjects with hypertension. All except one of the C3 glycopeptides proved to be ...
This study empowered the role of C3 N-glycosylation in T1D, showing value in distinguishing subjects with different diabetic complications. Being independent of the disease duration, these changes may...
Diabetic nephropathy is a common microvascular complication of diabetes mellitus. It is characterized by progressive chronic kidney disease (CKD) with decline of kidney function by hyperfiltration. On...
Dysregulated complement system is linked to pathophysiology of major depressive disorder (MDD). Childhood trauma has been associated with an increased incidence of adult depression via a putative mech...
The participants were 49 medication-free MDD patients and 45 healthy controls. All participants were asked to finish the Childhood Trauma Questionnaire, followed by blood sampling for measurement of p...
Peripheral plasma concentration of C3 and C3a in medication-free MDD group was significantly higher than that in the healthy controls; whereas the concentration of plasma C1q and CRP in depressed pati...
Our data suggest that complement C3 and C3a may be implicated in the pathophysiology of MDD, although traumatic childhood experiences were not associated with the circulating levels of complement C3, ...
Osteoarthritis (OA) is one of the leading causes of disability, affecting over 500 million adults worldwide. Previous studies have found that various inflammatory factors can contribute to the pathoge...
C3 glomerulopathy (C3G) is a complement-mediated disease. Although genetic studies are not required for diagnosis, they are valuable for treatment planning and prognosis prediction. The aim of this st...
Sixty pediatric C3G patients were included, divided into two groups based on complement-related gene mutations. Demographic and clinical-pathological findings, treatment modalities, and outcome data w...
Out of the 60 patients, 17 had mutations. The most common mutation was in the CFH gene (47%). The mean age at diagnosis was higher in the group with mutation (12.9 ± 3.6 vs. 11.2 ± 4.1 years, p = 0.03...
This study is the largest pediatric C3G study examining the relationship between genotype and phenotype. We showed that the mutation group often presented with asymptomatic urinary abnormalities, was ...